ClinicalTrials.gg
Status unknownNCT04128163Updated Nov 6, 2019

Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk

A Phase 3 interventional study of QL1206 and Placebos in Postmenopausal Osteoporosis, sponsored by Qilu Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to female participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-11-06.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2019), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2019, registered Sep 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies in Osteoporosis, Postmenopausal with a site in China — 1 open to participants now, 1 under way, none of them phase 3. Osteoporosis, Postmenopausal · China.

Planned enrollment
5th of 21
440 · median 148
Started
2019
with 5 others
Phase 3
7 of 25
none open now
Registered
14th of 25
by date

Among the 25 studies in Osteoporosis, Postmenopausal with a site in China, this one is the 5th largest by planned enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2019, is one of 7 in phase 3, and was the 14th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 25 studies in Osteoporosis, Postmenopausal with a site in China is open now. Recruiting first, the newest first:

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 50 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Osteoporosis, Postmenopausal with a site in China, or all of them as a file.
02

Study summary

A randomized, double-blind, two-group parallel, placebo-controlled clinical Phase III trial to compare the efficacy and safety of QL1206 and placebo in postmenopausal women with osteoporosis at high risk of fracture

Read the detailed description

This is a randomized, double-blind, two-group parallel, placebo-controlled clinical Phase III trial.

The primary objective is to evaluate the effect of QL1206 treatment compared with placebo in Chinese postmenopausal women with osteoporosis at high risk of fracture.

The secondary objective is to evaluate the clinical safety, immunogenicity and pharmacokinetic (PK) characteristics of QL1206 in women with osteoporosis at high risk of postmenopausal fracture

The exploratory purpose is to evaluate the effect of ADA on the characteristics of QL1206 PK and the relationship between QL1206 exposure and pharmacodynamic endpoints, efficacy and adverse events

Subjects would sequentially enrolled according to the protocol in one of two cohorts.Subjects would receive a single 60mg of QL1206 or placebo every 6 month for1 year(twice for one, subcutaneous injection) ,meanwhile taking 500 mg of calcium and 1000IU of vitamin D daily

03

Conditions studied

  • Postmenopausal Osteoporosis
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is willing to provide written .
  2. Ambulatory woman between the age of 50 and 85 years, inclusive.
  3. The subject has a BMD absolute value consistent with a T-score\<-2.5 and >-4.0 at either the lumbar spine or total hip
  4. All subjects must have at least one of following additional the risk factors:history of fracture(after 40 years),parental history of hip fracture, low (BMI≤19kg/m\^2), elderly (age≥65year),current smoker
  5. defined as >2 years postmenopausal, which can be >2 years of spontaneous amenorrhea or >2 years post surgical bilateral oophorectomy.

Exclusion criteria

Exclusion Criteria:

  1. Bone/metabolic disease:a. Any metabolic bone disease, e.g., osteomalacia or osteogenesis imperfecta,which may interfere with the interpretation of the findings.

    b. Paget's disease c. Cushing's disease d. Hyperprolactinemia

  2. Current hyperparathyroidism or hypoparathyroidism by medical record
  3. Thyroid condition: Hyperthyroidism or hypothyroidism.
  4. Rheumatoid arthritis

    -

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
440 participants (estimated)

Study arms

  • Experimental
    QL1206

    QL1206 injection (60mg:1ml) by subcutaneous injectionevery 6 month for two times. Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU

    Drug: QL1206

  • Placebo comparator
    Placebo

    placebo injection (1ml) by subcutaneous injectionevery 6 month for two times. Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU

    Drug: Placebos

Interventions

  • DrugQL1206

    subcutaneous injection of 60 mg(60mg:1ml), Q6M, twice for one year. Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU

    Also known as: Recombinant anti-RANKL human monoclonal antibody injection

  • DrugPlacebos

    subcutaneous injection of(1ml), Q6M, twice for one year. Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU

06

What researchers measure

Primary outcomes

  1. Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine from Baseline up to 12 months

    Bone mineral density (BMD) is the amount of bone mineral in bone tissue. BMD scan was done using dual energy x-ray absorptiometry (DXA). It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calcuated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. The analysis was performed by Analysis of Covariance (ANCOVA) model adjusted for treatment, region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as Baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the Last Observation Carried Forward (LOCF), provided the assessment was taken on or after at least three month on-therapy.

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Percent Change in BMD at the Lumbar Spine from Baseline up to 6 months

    BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value

    Time frame: Baseline and Month 6

  2. Percent change in BMD at the total hip, femoral neck and trochanter from Baseline up to 6 months and 12 months

    Percent change in BMD at the total hip, femoral neck and trochanter as measured BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value.

    Time frame: Baseline 、 Month 6 and Month 12

  3. Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) and Serum Procollagen Type I N Propeptideserum (s-PINP) from Baseline up to 6 months and 12 months

    s-CTX is biomarker of bone resorption and formation. s-CTX was assessed during Screening, Month 6 and Month 12 in the Double-blind Treatment Phase. The value during Screening was considered as the Baseline value. Percent change from Baseline was assessed as the value at the indicated visit minus the Baseline value divided by the Baseline value x 100. s-PINP is biomarker of bone resorption and formation. s-PINP was assessed during Screening, Month 6 and Month 12 in the Double-blind Treatment Phase. The value during Screening was considered as the Baseline value. Percent change from Baseline was assessed as the value at the indicated visit minus the Baseline value divided by the Baseline value x 100

    Time frame: Baseline 、 Month 6 and Month 12

  4. Adverse events and serious adverse events

    Evaluation of the follwing parameters. Including adverse events(AEs), change in physical examination findings, change in vital signs, clinical laboratory testing for systemic safety,including liver function,renal function ,compelete blood count,and clinical chemistries

    Time frame: Baseline、 Month 1、 Month 3、 Month 6 、 Month 9 and Month 12

  5. Immunogenicity

    Anti-denosumab antibody formation was assessed. Binding antibody and neutralizing antibody assays were used to assess number of participants with anti-denosumab antibody.

    Time frame: Baseline、 Month 3、 Month 6 、 Month 9 and Month 12

07

Study locations

1 of 1 sites recruiting
  • Shanghai sixth people's hospital
    Shanghai, Shanghai, China
    Recruiting
    • zhenlin zhang · Contact
    • zhenlin zhang · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Aug 2021, 26 months after the start.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's planned 26 months is close to that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2019
First posted
Oct 16, 2019
StartActual
Jun 5, 2019
Primary completionEst.
Aug 31, 2021
CompletionEst.
Dec 1, 2021
Last update
Nov 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04128163
Responsible party
Sponsor
First posted
Oct 16, 2019
Start date
Jun 5, 2019
Primary completion
Aug 31, 2021 (estimated)
Completion
Dec 1, 2021 (estimated)
Last update
Nov 6, 2019

Study contacts

shunjiang yu, CMO
Contact
shunjiang.yu@qilu-pharma.com
0531-83129659
zhenlin zhang
principal investigator · Shanghai 6th People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QL1206

Start the discussion